GNGT1 is a potential prognostic and immunologic biomarker in gastric cancer

Abstract Gastric cancer(GC) is the fifth most common type of cancer worldwide and ranks third in terms of cancer-related mortality. Immunotherapy has shown promising outcomes and greatly extended survival in individuals with advanced stomach cancer. To improve the immunotherapy response in patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Xuchong Huang, Juan Lin, Jian Wang, Weifeng Yang, Wenquan Ou, Xing Huang, Jiahua Chen, Zixing Zhang, Xiaohua Wu
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-08297-4
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849238539049369600
author Xuchong Huang
Juan Lin
Jian Wang
Weifeng Yang
Wenquan Ou
Xing Huang
Jiahua Chen
Zixing Zhang
Xiaohua Wu
author_facet Xuchong Huang
Juan Lin
Jian Wang
Weifeng Yang
Wenquan Ou
Xing Huang
Jiahua Chen
Zixing Zhang
Xiaohua Wu
author_sort Xuchong Huang
collection DOAJ
description Abstract Gastric cancer(GC) is the fifth most common type of cancer worldwide and ranks third in terms of cancer-related mortality. Immunotherapy has shown promising outcomes and greatly extended survival in individuals with advanced stomach cancer. To improve the immunotherapy response in patients with GC, it is necessary to discover new molecular targets. The associations among G protein subunit gamma transducin 1(GNGT1) expression, clinicopathological features, and prognosis were assessed via the UALCAN and Kaplan-Meier databases. The CIBERSORT algorithm in R software and single-sample gene set enrichment analysis(ssGSEA) were used to analyse the proportions of infiltrating immune cells in the high-expression group and the low-expression group.GNGT1 expression was substantially greater in GC tissues than in normal tissues, and patients with GC who had high GNGT1 expression had worse clinicopathological characteristics and survival outcomes. Immunohistochemistry(IHC) experiments on stomach adenocarcinoma(STAD) samples confirmed the aberrant expression of GNGT1 and its association with a poor prognosis. Subsequent investigations revealed substantial negative correlations between GNGT1 and tumour mutational burden(TMB), microsatellite instability(MSI), immune cell infiltration, immune cell gene marker expression and immunological checkpoint expression in patients with STAD.GNGT1 is a reliable biomarker in patients with GC that also has an immunomodulatory function in this disease and may accelerate GC development by suppressing the infiltration of T cells, dendritic cells, M1 macrophages and B cells.
format Article
id doaj-art-55a88f3e11344d97ace0e43ab91e815d
institution Kabale University
issn 2045-2322
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-55a88f3e11344d97ace0e43ab91e815d2025-08-20T04:01:35ZengNature PortfolioScientific Reports2045-23222025-07-0115112010.1038/s41598-025-08297-4GNGT1 is a potential prognostic and immunologic biomarker in gastric cancerXuchong Huang0Juan Lin1Jian Wang2Weifeng Yang3Wenquan Ou4Xing Huang5Jiahua Chen6Zixing Zhang7Xiaohua Wu8Department of Clinical Medicine, Fujian Medical UniversityDepartment of Operating Room, Nanping First Hospital Affiliated to Fujian Medical UniversityDepartment of General Surgery, Nanping First Hospital Affiliated to Fujian Medical UniversityDepartment of General Surgery, Nanping First Hospital Affiliated to Fujian Medical UniversityDepartment of General Surgery, Nanping First Hospital Affiliated to Fujian Medical UniversityDepartment of General Surgery, Nanping First Hospital Affiliated to Fujian Medical UniversityDepartment of Clinical Medicine, Fujian Medical UniversityDepartment of Clinical Medicine, Fujian Medical UniversityDepartment of General Surgery, Nanping First Hospital Affiliated to Fujian Medical UniversityAbstract Gastric cancer(GC) is the fifth most common type of cancer worldwide and ranks third in terms of cancer-related mortality. Immunotherapy has shown promising outcomes and greatly extended survival in individuals with advanced stomach cancer. To improve the immunotherapy response in patients with GC, it is necessary to discover new molecular targets. The associations among G protein subunit gamma transducin 1(GNGT1) expression, clinicopathological features, and prognosis were assessed via the UALCAN and Kaplan-Meier databases. The CIBERSORT algorithm in R software and single-sample gene set enrichment analysis(ssGSEA) were used to analyse the proportions of infiltrating immune cells in the high-expression group and the low-expression group.GNGT1 expression was substantially greater in GC tissues than in normal tissues, and patients with GC who had high GNGT1 expression had worse clinicopathological characteristics and survival outcomes. Immunohistochemistry(IHC) experiments on stomach adenocarcinoma(STAD) samples confirmed the aberrant expression of GNGT1 and its association with a poor prognosis. Subsequent investigations revealed substantial negative correlations between GNGT1 and tumour mutational burden(TMB), microsatellite instability(MSI), immune cell infiltration, immune cell gene marker expression and immunological checkpoint expression in patients with STAD.GNGT1 is a reliable biomarker in patients with GC that also has an immunomodulatory function in this disease and may accelerate GC development by suppressing the infiltration of T cells, dendritic cells, M1 macrophages and B cells.https://doi.org/10.1038/s41598-025-08297-4G protein subunit gamma transducin 1Gastric cancerBiomarkerImmune microenvironmentBioinformatics analysisDrug sensitivity
spellingShingle Xuchong Huang
Juan Lin
Jian Wang
Weifeng Yang
Wenquan Ou
Xing Huang
Jiahua Chen
Zixing Zhang
Xiaohua Wu
GNGT1 is a potential prognostic and immunologic biomarker in gastric cancer
Scientific Reports
G protein subunit gamma transducin 1
Gastric cancer
Biomarker
Immune microenvironment
Bioinformatics analysis
Drug sensitivity
title GNGT1 is a potential prognostic and immunologic biomarker in gastric cancer
title_full GNGT1 is a potential prognostic and immunologic biomarker in gastric cancer
title_fullStr GNGT1 is a potential prognostic and immunologic biomarker in gastric cancer
title_full_unstemmed GNGT1 is a potential prognostic and immunologic biomarker in gastric cancer
title_short GNGT1 is a potential prognostic and immunologic biomarker in gastric cancer
title_sort gngt1 is a potential prognostic and immunologic biomarker in gastric cancer
topic G protein subunit gamma transducin 1
Gastric cancer
Biomarker
Immune microenvironment
Bioinformatics analysis
Drug sensitivity
url https://doi.org/10.1038/s41598-025-08297-4
work_keys_str_mv AT xuchonghuang gngt1isapotentialprognosticandimmunologicbiomarkeringastriccancer
AT juanlin gngt1isapotentialprognosticandimmunologicbiomarkeringastriccancer
AT jianwang gngt1isapotentialprognosticandimmunologicbiomarkeringastriccancer
AT weifengyang gngt1isapotentialprognosticandimmunologicbiomarkeringastriccancer
AT wenquanou gngt1isapotentialprognosticandimmunologicbiomarkeringastriccancer
AT xinghuang gngt1isapotentialprognosticandimmunologicbiomarkeringastriccancer
AT jiahuachen gngt1isapotentialprognosticandimmunologicbiomarkeringastriccancer
AT zixingzhang gngt1isapotentialprognosticandimmunologicbiomarkeringastriccancer
AT xiaohuawu gngt1isapotentialprognosticandimmunologicbiomarkeringastriccancer